Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
复制标题
DOI：
10.3390/ijms22062800
复制
发表时间：
2021-03-10
影响因子：
5.6
通讯作者：
Theodorescu D
中科院分区：
文献类型：
--
作者：
de Jong FC;Rutten VC;Zuiverloon TCM;Theodorescu D
在高风险非肌肉浸润性膀胱癌（HR-NMIBC）中，患者结局受到Bacillus-Calmette Guérin（BCG）治疗缺乏反应的负面影响。对基于顺铂的新辅助化疗缺乏反应和顺铂不合格降低了肌层浸润性膀胱癌（MIBC）患者的成功治疗结局。PD-1/PD-L1免疫检查点抑制剂（ICI）在转移性疾病中的有效性刺激了其作为HR-NMIBC和MIBC患者治疗选择的评价。然而，观察到的反应、免疫相关不良事件和与ICI相关的高成本为开发改善患者分层、增强抗肿瘤作用和降低毒性的方法提供了动力。在这里，我们回顾了HR-NMIBC和MIBC中PD-1/PD-L1抑制所带来的挑战和机遇。我们强调了该领域需要解决的差距，以改善患者结局，包括用于缓解分层的生物标志物和与PD-1/PD-L1阻断剂的潜在协同联合治疗方案。
In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to Bacillus-Calmette Guérin (BCG) treatment. Lack of response to cisplatin-based neoadjuvant chemotherapy and cisplatin ineligibility reduces successful treatment outcomes in muscle-invasive bladder cancer (MIBC) patients. The effectiveness of PD-1/PD-L1 immune checkpoint inhibitors (ICI) in metastatic disease has stimulated its evaluation as a treatment option in HR-NMIBC and MIBC patients. However, the observed responses, immune-related adverse events and high costs associated with ICI have provided impetus for the development of methods to improve patient stratification, enhance anti-tumorigenic effects and reduce toxicity. Here, we review the challenges and opportunities offered by PD-1/PD-L1 inhibition in HR-NMIBC and MIBC. We highlight the gaps in the field that need to be addressed to improve patient outcome including biomarkers for response stratification and potentially synergistic combination therapy regimens with PD-1/PD-L1 blockade.
登录
查看更多内容
DOI：
10.1084/jem.20101159
发表时间：
2011-09-26
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Fuertes MB;Kacha AK;Kline J;Woo SR;Kranz DM;Murphy KM;Gajewski TF
通讯作者：
Gajewski TF
影响因子：
11.2
作者：
Burnette BC;Liang H;Lee Y;Chlewicki L;Khodarev NN;Weichselbaum RR;Fu YX;Auh SL
通讯作者：
Auh SL
影响因子：
3.4
作者：
Aydin, Ahmet Murat;Baydar, Dilek E.;Bilen, Cenk Y.
通讯作者：
Bilen, Cenk Y.
影响因子：
11.2
作者：
Bunt, Stephanie K.;Yang, Linglin;Ostrand-Rosenberg, Suzanne
通讯作者：
Ostrand-Rosenberg, Suzanne
影响因子：
3.4
作者：
Daro-Faye, Mame;Kassouf, Wassim;Sargos, Paul
通讯作者：
Sargos, Paul